RayKnowChina Research Map
Shortlist0

GuangzhouSun Yat-sen University

Third Affiliated Hospital of Sun Yat-sen University

中山大学附属第三医院

Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Third Affiliated Hospital of Sun Yat-sen University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌10 papers led
  2. Hepatocellular carcinoma肝细胞癌171 papers led3 open trials led
  3. Stomach cancer胃癌15 papers led
  4. Hepatoblastoma肝母细胞瘤1 paper led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Multiple myeloma多发性骨髓瘤4 papers led
  9. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  10. Beta thalassaemiaβ 地中海贫血0 papers led
  11. Fanconi anaemia范可尼贫血1 paper led
  12. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病39 papers led2 open trials led
  13. Myasthenia gravis重症肌无力0 papers led1 open trial led
  14. Moyamoya disease烟雾病3 papers led
  15. Wilson disease肝豆状核变性(Wilson 病)0 papers led
  16. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎22 papers led
  17. Takayasu arteritis大动脉炎2 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  20. Behçet disease白塞病0 papers led
  21. Alport syndromeAlport 综合征1 paper led
  22. IgA nephropathyIgA 肾病0 papers led
  23. Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
  24. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  25. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  26. Hereditary angioedema遗传性血管性水肿0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, IgG4-related disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 10 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 2220242025: 332025

23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueSide effects & quality of lifeRecurrent / metastatic disease
Departments in papersRadiation oncologyRadiology / nuclear medicineENT / head & neck surgery
Papers it led10
  1. EBNA1 Targeted Ultra-Small Near-Infrared Persistent Luminescent Nano-Inhibitor for Theranostics of EBV-Associated Cancer.2025Advanced healthcare materials
  2. Video tracking-based mandibular movement kinematic analysis in patients with nasopharyngeal carcinoma.2025European journal of medical researchFree full text
  3. Effects of minimum monitor unit per dynamic control point on intensity-modulated radiotherapy planning for nasopharyngeal carcinoma: A retrospective study.2025Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  4. Characteristics of Tongue Pressure Measured by Novel Multisite Flexible Sensors in Nasopharyngeal Carcinoma Patients With Dysphagia.2024Archives of physical medicine and rehabilitation
  5. Increased CCT5 expression is a potential unfavourable factor promoting the growth of nasopharyngeal carcinoma.2024The Journal of international medical researchFree full text
  6. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?2023Cancer medicineFree full text
  7. Effect of Intensive Oropharyngeal Training on Radiotherapy-Related Dysphagia in Nasopharyngeal Carcinoma Patients.2022Dysphagia
  8. Influence of beamlet width on dynamic IMRT plan quality in nasopharyngeal carcinoma.2022PeerJFree full text
  9. Prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma: A retrospective study.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  10. Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Chinese-language papers (not in the count)2
  1. [The objective and material selection of skull base reconstruction after radiotherapy for nasopharyngeal carcinoma].2025Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [miR-18a enhances the radiosensitivity of nasopharyngeal carcinoma cells through inducing autophagy].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
More papers found outside PubMed (not counted)6
  1. Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma2025Open Research (University of Surrey)article
  2. Prognostic Value of Parapharyngeal Involvement Subclassifications Divided by Parapharyngeal Muscles in Nasopharyngeal Carcinoma: A Study of 1752 Patients from Two Centers2024Research Squarepreprint
  3. The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.2024Journal of Clinical Oncologyconference-abstract
  4. Synthetic computed tomography generation from multi-sequence magnetic resonance images for nasopharyngeal carcinoma treatment planning via cycle-consistent generative adversarial network2023Research Squarepreprint
  5. Effect of Exercise on Sternoceleidomastoid Muscular Fibrosis after Radiotherapy for Nasopharyngeal Carcinoma Patients Analyzed by Shear-Wave Elastography2022Rehabilitation Medicinearticle
  6. Effect of the number of control points on the plan quality of intensity-modulated radiotherapy for nasopharyngeal carcinoma2021Journal of Radiation Research and Applied Sciencesarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 171 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
171
2021–2025
Trials led
11
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 383820212022: 292920222023: 363620232024: 222220242025: 41412025

14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05984511

    Age 18 years to 75 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  2. Recruiting
    Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
    Phase
    N/A
    Started
    2022-08
    Registry
    NCT05484908

    Age 18 years to 65 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  3. Not yet recruiting
    Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06900478

    Age 18 years to 80 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  4. Recruiting
    A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07589244

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  5. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  6. Recruiting
    Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT06746701

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya Hospital; 1 listed hospital as study siteChangsha, Guangzhou

  7. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncology
Papers it led171
  1. Diagnostic performance of dual-layer spectral detector CT derived from the arterial and portal venous phases in small HCC (≤ 30 mm): comparison with multiphase CT and MRI.2026Abdominal radiology (New York)
  2. Multi-faceted nanodrug reinforcing metalloimmunotherapy for hepatocellular carcinoma.2026Biomaterials
  3. Hyperbaric oxygen targets RCN1 to modulate ER-mitochondria crosstalk and ameliorate sorafenib resistance in hepatocellular carcinoma.2026Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  4. LI-RADS categories and clinicopathological features predict recurrence-free survival in patients with radical resected hepatocellular carcinoma.2026European journal of radiology
  5. Alcohol activates ATF4/LPLA2-mediated BMP metabolism to enhance HBV-induced hepatocellular carcinogenesis.2026Journal of hepatology
  6. RP11-439C15.4 inhibits the malignant progression of hepatocellular carcinoma via binding to DHX9 and facilitating its degradation.2025Acta biochimica et biophysica SinicaFree full text
  7. CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c-Myc Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  8. Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  9. Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease.2025Annals of hepatology
  10. Predicting the occurrence of liver injury induced by immune checkpoint inhibitors in hepatocellular carcinoma patients: a retrospective analysis.2025BMC cancerFree full text
  11. Dynamic changes in liver stiffness measurement by 2D shear-wave elastography predict hepatocellular carcinoma in patients with chronic hepatitis B and well-controlled viremia: a retrospective study.2025BMC gastroenterologyFree full text
  12. A self-gelling hemostatic powder boosting radiotherapy-elicited NK cell immunity to combat postoperative hepatocellular carcinoma relapse.2025Biomaterials
  13. Lactate accumulation drives hepatocellular carcinoma metastasis through facilitating tumor-derived exosome biogenesis by Rab7A lactylation.2025Cancer letters
  14. NEIL3 Deficiency Enhances HCC Cell Sensitivity to Oxaliplatin by Inhibiting the Fanconi Anaemia Pathway.2025Cell biology international
  15. Nucleolar NOL9 regulated by DNA methylation promotes hepatocellular carcinoma growth through activation of Wnt/β-catenin signaling pathway.2025Cell death & diseaseFree full text
  16. Tissue-resident peripheral helper T cells foster hepatocellular carcinoma immune evasion by promoting regulatory B-cell expansion.2025Chinese medical journalFree full text
  17. Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  18. Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: A network meta-analysis based on risk probability assessment.2025Critical reviews in oncology/hematology
  19. Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  20. MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response.2025European radiology
  21. Three-dimensional MR elastography-based stiffness for assessing the status of Ki67 proliferation index and Cytokeratin-19 in hepatocellular carcinoma.2025European radiology
  22. METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response.2025FEBS open bioFree full text
  23. Serglycin's role in primary liver cancer: insights into tumor microenvironment and macrophage interaction.2025Frontiers in immunologyFree full text
  24. HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  25. Case Report: Split liver transplantation for graft liver failure due to antibody-mediated rejection after immune checkpoint inhibitor therapy.2025Frontiers in immunologyFree full text
  26. Integrative spatial and single-cell transcriptomics elucidate programmed cell death-driven tumor microenvironment dynamics in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  27. Unraveling the potential mechanism and prognostic value of pentose phosphate pathway in hepatocellular carcinoma: a comprehensive analysis integrating bulk transcriptomics and single-cell sequencing data.2025Functional & integrative genomics
  28. CircPIK3C3 inhibits hepatocellular carcinoma progression and lenvatinib resistance by suppressing the Wnt/β-catenin pathway via the miR-452-5p/SOX15 axis.2025Genomics
  29. Clinical Features of HBV-Related HCC in Long-Term NAs-Treated Versus Untreated Patients.2025Journal of cellular and molecular medicineFree full text
  30. Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization.2025Journal of clinical laboratory analysisFree full text
  31. CRSP8-driven fatty acid metabolism reprogramming enhances hepatocellular carcinoma progression by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.2025Journal of experimental & clinical cancer research : CRFree full text
  32. Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase.2025Journal of gastroenterology and hepatology
  33. Intertumoral Heterogeneity Based on MRI Radiomic Features Estimates Recurrence in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRI
  34. A facile combined therapy of chemotherapeutic agent and microRNA for hepatocellular carcinoma using non-cationic nanogel.2025Journal of materials chemistry. B
  35. Drug-loaded indocyanine green J-aggregates activate metalloimmunotherapy for sustained photothermal therapy of hepatocellular carcinoma.2025Journal of nanobiotechnologyFree full text
  36. Radiotherapy plus a self-gelation powder encapsulating tRF5-GlyGCC inhibitor potentiates natural kill cell immunity to prevent hepatocellular carcinoma recurrence.2025Journal of nanobiotechnologyFree full text
  37. EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis.2025Journal of translational medicineFree full text
  38. The hybrid lipoplex induces cytoskeletal rearrangement via autophagy/RhoA signaling pathway for enhanced anticancer gene therapy.2025Nature communicationsFree full text
  39. Semiquantitative analysis of 18F-aluminum fluoride fibroblast activation protein inhibitor 42 PET/computed tomography in primary liver cancer and factors influencing imaging positivity rates.2025Nuclear medicine communications
  40. Oncolytic virus therapy in hepatocellular carcinoma.2025Oncology researchFree full text
  41. Interactive Explainable Deep Learning Model for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI: A Retrospective, Multicenter, Diagnostic Study.2025Radiology. Imaging cancerFree full text
  42. Machine learning-assisted multi-dimensional transcriptomic analysis of cytoskeleton-related molecules and their relationship with prognosis in hepatocellular carcinoma.2025Scientific reportsFree full text
  43. Late course adaptive radiotherapy based on tumor volume reduction decreases Gastrointestinal toxicity for abdominal lymph node metastasis of hepatocellular carcinoma.2025Scientific reportsFree full text
  44. Development and clinical validation of a novel platelet count-based nomogram for predicting microvascular invasion in HCC.2025Scientific reportsFree full text
  45. Comparative analysis of hepatectomy for HCC with PVTT: Insights from a 30-year single-center experience: Hepatectomy for HCC with PVTT.2025Surgical oncology
  46. Predicting early recurrence of hepatocellular carcinoma after thermal ablation based on longitudinal MRI with a deep learning approach.2025The oncologistFree full text
  47. Anatomical thermal ablation as an alternative to surgical resection for subcapsular hepatocellular carcinoma.2024Abdominal radiology (New York)
  48. Mean ADC values and arterial phase hyperintensity discriminate small (≤ 3 cm) well-differentiated hepatocellular carcinoma from dysplastic nodule.2024Abdominal radiology (New York)
  49. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.2024Academic radiology
  50. Clinicopathologic features and tumor immune microenvironment of lymphocyte-rich hepatocellular carcinoma.2024Annals of diagnostic pathology
  51. Clinical outcomes of modified transarterial chemoembolization vs. drug-eluting bead transarterial chemoembolization as initial treatment for single hepatocellular carcinoma: a propensity score matching analysis.2024Annals of medicineFree full text
  52. A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  53. Dynamic network biomarker C1QTNF1 regulates tumor formation at the tipping point of hepatocellular carcinoma.2024Biomolecules & biomedicineFree full text
  54. Evaluation of the effectiveness of surgical resection and ablation for the treatment of early-stage hepatocellular carcinoma: A retrospective cohort study.2024Cancer reports (Hoboken, N.J.)Free full text
  55. COLEC10 inhibits the stemness of hepatocellular carcinoma by suppressing the activity of β-catenin signaling.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  56. Evaluating the impact of treatment sequencing on outcomes in hepatocellular carcinoma: a comparative analysis of TACE and systemic therapies.2024Clinical and experimental medicineFree full text
  57. A Novel Oncogenic Role of Disulfidptosis-related Gene SLC7A11 in Anti-tumor Immunotherapy Response to Human Cancers.2024Current cancer drug targets
  58. Insights into the accumulation and hepatobiliary transport of bisphenols (BPs) in liver and bile.2024Environmental research
  59. New strategy of LI-RADS v2018 to improve the sensitivity for small hepatocellular carcinoma ≤ 3.0 cm on extracellular-contrast enhanced MRI.2024European journal of radiology
  60. Assessment of arterial-phase hyperenhancement and late-phase washout of hepatocellular carcinoma-a meta-analysis of contrast-enhanced ultrasound (CEUS) with SonoVue® and Sonazoid®.2024European radiology
  61. Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.2024Hepatology (Baltimore, Md.)
  62. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways.2024International immunopharmacology
  63. Interleukin-25 as a Potential Biomarker in Lung Metastasis of Hepatocellular Carcinoma with HBV History in Chinese Patients: A Single Center, Case-control Study.2024International journal of medical sciencesFree full text
  64. Distribution of per- and polyfluoroalkyl substances in blood, serum, and urine of patients with liver cancer and associations with liver function biomarkers.2024Journal of environmental sciences (China)
  65. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study.2024MedicineFree full text
  66. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis.2024Molecular cancerFree full text
  67. Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.2024Scientific reportsFree full text
  68. Microinvasion in hepatocellular carcinoma: predictive factor and application for definition of clinical target volume for radiotherapy.2024World journal of surgical oncologyFree full text
  69. 18F-FDG PET/CT-based radiomics nomogram for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma: a two-center study.2023Abdominal radiology (New York)
  70. The Conserved LncRNA DIO3OS Restricts Hepatocellular Carcinoma Stemness by Interfering with NONO-Mediated Nuclear Export of ZEB1 mRNA.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  71. Hepatitis B virus X protein induces p16 gene promoter methylation through upregulation of DNA methylation transferases DNMT1 and DNMT3A.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  72. Letter: Causal relationship between aspirin and the risk of hepatocellular carcinoma remains unproven.2023Alimentary pharmacology & therapeutics
  73. Transcriptional analysis of the expression and prognostic value of lipid droplet-localized proteins in hepatocellular carcinoma.2023BMC cancerFree full text
  74. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.2023Biomaterials
  75. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  76. PTTG1 Reprograms Asparagine Metabolism to Promote Hepatocellular Carcinoma Progression.2023Cancer research
  77. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence.2023Current oncology (Toronto, Ont.)Free full text
  78. Splicing factor SNRPA associated with microvascular invasion promotes hepatocellular carcinoma metastasis through activating NOTCH1/Snail pathway and is mediated by circSEC62/miR-625-5p axis.2023Environmental toxicology
  79. Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma.2023EpigeneticsFree full text
  80. The value of quantitative MR elastography-based stiffness for assessing the microvascular invasion grade in hepatocellular carcinoma.2023European radiology
  81. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.2023Free radical biology & medicine
  82. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  83. Preoperative prediction model of microvascular invasion in patients with hepatocellular carcinoma.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  84. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from2023Hepatology international
  85. Lnc-ZEB2-19 Inhibits the Progression and Lenvatinib Resistance of Hepatocellular Carcinoma by Attenuating the NF-κB Signaling Pathway through the TRA2A/RSPH14 Axis.2023International journal of biological sciencesFree full text
  86. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.2023Investigational new drugs
  87. Response to 'Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC' by Yang et al.2023Journal for immunotherapy of cancerFree full text
  88. Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma.2023Journal of experimental & clinical cancer research : CRFree full text
  89. RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization.2023Journal of experimental & clinical cancer research : CRFree full text
  90. CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect.2023Journal of experimental & clinical cancer research : CRFree full text
  91. Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.2023Journal of hepatology
  92. Expression and prognostic value of DNA sensors in hepatocellular carcinoma.2023Journal of leukocyte biology
  93. Efficacy of Multiple Modified Methods of Criteria for LR-M Liver Nodules of Different Sizes: Clinical Practice and Discussion in CEUS LI-RADS Version 2017.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  94. Long-term Outcomes of Patients with Hepatocellular Carcinoma Who Underwent Microwave Ablation after Downstaging with Transarterial Chemoembolization to Barcelona Clinic Liver Cancer Stage A.2023Journal of vascular and interventional radiology : JVIR
  95. Preoperative Transarterial Chemoembolization of Hepatic Inflammatory Pseudotumor-Like Follicular Dendritic Cell Sarcoma to Downstage to Resection.2023Journal of vascular and interventional radiology : JVIR
  96. COLEC10 Induces Endoplasmic Reticulum Stress by Occupying GRP78 and Inhibits Hepatocellular Carcinoma.2023Laboratory investigation; a journal of technical methods and pathology
  97. PTTG1 alleviates acute alcoholic liver injury by inhibiting endoplasmic reticulum stress-induced hepatocyte pyroptosis.2023Liver international : official journal of the International Association for the Study of the Liver
  98. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells.2023Nature communicationsFree full text
  99. Dual-Energy CT Deep Learning Radiomics to Predict Macrotrabecular-Massive Hepatocellular Carcinoma.2023Radiology
  100. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.2023RadiologyFree full text
  101. TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm).2023Technology in cancer research & treatmentFree full text
  102. Erythroid-transdifferentiated myeloid cells promote portal vein tumor thrombus in hepatocellular carcinoma.2023TheranosticsFree full text
  103. Development of a Risk Classifier to Predict Tumor Recurrence and Lenvatinib Benefits in Hepatocellular Carcinoma After Liver Transplantation.2023Transplantation proceedings
  104. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy.2023World journal of gastroenterologyFree full text
  105. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.2022AJR. American journal of roentgenologyRCT
  106. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?2022Abdominal radiology (New York)
  107. Prevention of major biliary complications by fusion imaging for thermal ablation of malignant liver tumors adjacent to the bile ducts: a preliminary comparative study.2022Abdominal radiology (New York)
  108. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.2022Abdominal radiology (New York)
  109. Association of phenotypic transformation of circulating tumor cells and early recurrence in patients with hepatocellular carcinoma following liver transplantation.2022Asian journal of surgery
  110. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.2022BMC cancerFree full text
  111. Effect of alcohol on clinical complications of hepatitis virus-induced liver cirrhosis: a consecutive ten-year study.2022BMC gastroenterologyFree full text
  112. Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma.2022BMC surgeryFree full text
  113. Sorafenib suppresses the activation of type I interferon pathway induced by RLR-MAVS and cGAS-STING signaling.2022Biochemical and biophysical research communications
  114. Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma.2022Biomaterials
  115. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.2022Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  116. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.2022Cancer immunology, immunotherapy : CIIFree full text
  117. High Expression of POGK Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma.2022Current oncology (Toronto, Ont.)Free full text
  118. MR elastography as a biomarker for prediction of early and late recurrence in HBV-related hepatocellular carcinoma patients before hepatectomy.2022European journal of radiologyFree full text
  119. MR Elastography-Based Shear Strain Mapping for Assessment of Microvascular Invasion in Hepatocellular Carcinoma.2022European radiologyFree full text
  120. Deep Learning-Based Classification of Hepatocellular Nodular Lesions on Whole-Slide Histopathologic Images.2022Gastroenterology
  121. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.2022GenesFree full text
  122. DNA N6-methyladenine involvement and regulation of hepatocellular carcinoma development.2022Genomics
  123. A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes.2022Hepatology international
  124. Identification and Validation of a Prognostic Model Based on Three MVI-Related Genes in Hepatocellular Carcinoma.2022International journal of biological sciencesFree full text
  125. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.2022International journal of cancer
  126. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.2022Journal for immunotherapy of cancerFree full text
  127. Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-κBp65/HK2 signalling.2022Journal of experimental & clinical cancer research : CRFree full text
  128. The Immune Landscape of Hepatitis B Virus-Related Acute Liver Failure by Integration Analysis.2022Journal of immunology researchFree full text
  129. Black phosphorus-Au-thiosugar nanosheets mediated photothermal induced anti-tumor effect enhancement by promoting infiltration of NK cells in hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  130. Laminaria japonica Peptides Suppress Liver Cancer by Inducing Apoptosis: Possible Signaling Pathways and Mechanism.2022Marine drugsFree full text
  131. CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib.2022Molecular carcinogenesis
  132. Identification of circRNAs involved in the development of hepatocellular carcinoma after insufficient radiofrequency ablation.2022Neoplasma
  133. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.2022World journal of gastroenterologyFree full text
  134. Diagnostic accuracy of 3D magnetic resonance elastography for assessing histologic grade of hepatocellular carcinoma: comparison of three methods for positioning region of interest.2021Abdominal radiology (New York)Free full text
  135. Feasibility of 3D US/CEUS-US/CEUS fusion imaging-based ablation planning in liver tumors: a retrospective study.2021Abdominal radiology (New York)
  136. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.2021Abdominal radiology (New York)
  137. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  138. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.2021AgingFree full text
  139. Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma.2021AgingFree full text
  140. Value of KPNA4 as a diagnostic and prognostic biomarker for hepatocellular carcinoma.2021AgingFree full text
  141. HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G1/S cycle.2021AutophagyFree full text
  142. Anatomical sites (Takasaki's segmentation) predicts the recurrence-free survival of hepatocellular carcinoma.2021BMC surgeryFree full text
  143. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.2021Biochemical and biophysical research communications
  144. HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues.2021Briefings in bioinformatics
  145. Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection.2021Canadian journal of gastroenterology & hepatologyFree full text
  146. Intratumoral CD45+CD71+ erythroid cells induce immune tolerance and predict tumor recurrence in hepatocellular carcinoma.2021Cancer letters
  147. Circular RNA circ-102,166 acts as a sponge of miR-182 and miR-184 to suppress hepatocellular carcinoma proliferation and invasion.2021Cellular oncology (Dordrecht, Netherlands)Free full text
  148. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.2021Clinical and experimental medicine
  149. Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis.2021Clinics and research in hepatology and gastroenterology
  150. Prognostic Significance of Hematopoietic-cell Serglycin for the Survival of Hepatocellular Carcinoma: A Single-center Retrospective Study.2021Combinatorial chemistry & high throughput screening
  151. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria.2021European journal of gastroenterology & hepatology
  152. Diagnostic performance of LI-RADS for MRI and CT detection of HCC: A systematic review and diagnostic meta-analysis.2021European journal of radiology
  153. Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI.2021European radiology
  154. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.2021European radiology
  155. TMEM2 binds to CSNK2A3 to inhibit HBV infection via activation of the JAK/STAT pathway.2021Experimental cell research
  156. Letter to the Editor: Should Growth Pattern of Hepatocellular Carcinoma Be Constant and Homogenous?2021Hepatology (Baltimore, Md.)
  157. Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning.2021Journal of cancer research and clinical oncologyFree full text
  158. circNFATC3 sponges miR-548I acts as a ceRNA to protect NFATC3 itself and suppressed hepatocellular carcinoma progression.2021Journal of cellular physiology
  159. Phosphorylation of NF-κBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target.2021Journal of experimental & clinical cancer research : CRFree full text
  160. Accuracies of Chemical Shift In/Opposed Phase and Chemical Shift Encoded Magnetic Resonance Imaging to Detect Intratumoral Fat in Hepatocellular Carcinoma.2021Journal of magnetic resonance imaging : JMRI
  161. Expression and prognostic roles of PRDXs gene family in hepatocellular carcinoma.2021Journal of translational medicineFree full text
  162. Utility of Fusion Imaging for Percutaneous Thermal Ablation of Hepatocellular Carcinoma in the Caudate Lobe.2021Journal of vascular and interventional radiology : JVIR
  163. Dynamic Contrast-Enhanced Ultrasound Radiomics for Hepatocellular Carcinoma Recurrence Prediction After Thermal Ablation.2021Molecular imaging and biology
  164. GTSE1 promotes SNAIL1 degradation by facilitating its nuclear export in hepatocellular carcin oma cells.2021Molecular medicine reportsFree full text
  165. Prognostic Value of Serum Apolipoprotein B to Apolipoprotein A-I Ratio in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.2021Oncology research and treatmentFree full text
  166. Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma.2021Radiographics : a review publication of the Radiological Society of North America, Inc
  167. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B.2021Radiology
  168. Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.2021The oncologistFree full text
  169. Intra-Procedural CT/MR-Ultrasound Fusion Imaging Helps to Improve Outcomes of Thermal Ablation for Hepatocellular Carcinoma: Results in 502 Nodules.2021Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  170. Clinical and Contrast-enhanced Ultrasound Characteristics of Epithelioid and Classic Hepatic Angiomyolipoma: Comparison With Alpha-fetoprotein-negative Hepatocellular Carcinoma.2021Ultrasound in medicine & biology
  171. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)2
  1. [Multi-omics combined test performance effectiveness on opportunistic screening of high-risk liver cancer population].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Effect of HBV DNA load on the safety and prognosis of systematic therapy in advanced hepatocellular carcinoma].2024Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status27
  1. TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTTRecruitingNCT05984511Lead sponsorN/AStart 2023-08
  2. Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCCRecruitingNCT05484908Lead sponsorN/AStart 2022-08
  3. TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCStatus unknownNCT05250843Lead sponsorPhase 2/Phase 3Start 2022-05
  4. Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver TransplantationStatus unknownNCT04564313Lead sponsorPhase 1Start 2020-09
  5. Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control TrialStatus unknownNCT02817685Lead sponsorStart 2016-05
  6. Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver TransplantationStatus unknownNCT02399735Lead sponsorPhase 1Start 2014-10
  7. Radiomics for Diagnosing Liver Diseases and Evaluating ProgressionStatus unknownNCT03221049Lead sponsorStart 2011-01
  8. Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCCNot yet recruitingNCT06900478Lead (inferred)Phase 2Start 2025-03
  9. Ablation in Combination With Lenvatinib and Anti-PD-1 AntibodiesStatus unknownNCT05803928Lead (inferred)Phase 1Start 2024-01
  10. Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving ImmunotherapyStatus unknownNCT05620004Lead (inferred)Phase 1/Phase 2Start 2021-11
  11. A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)CompletedNCT03086564Lead (inferred)Phase 1/Phase 2Start 2017-05
  12. A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCCRecruitingNCT07589244Study sitePhase 2/Phase 3Start 2026-05
  13. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular CarcinomaNot yet recruitingNCT06779461Study sitePhase 3Start 2025-01
  14. Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.RecruitingNCT06746701Study siteStart 2023-05
  15. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  16. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  17. A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250Study siteStart 2024-07
  18. A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedNCT05975645Study sitePhase 1Start 2023-08
  19. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationStatus unknownNCT05313282Study sitePhase 3Start 2022-06
  20. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)Status unknownNCT05214339Study sitePhase 2Start 2022-03
  21. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma PatientsStatus unknownNCT05343832Study siteStart 2021-11
  22. Performance Evaluation (Sensitivity/Specificity) of HelioLiver Test for Detection of HCCCompletedNCT05059665Study siteStart 2020-04
  23. Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Study sitePhase 2/Phase 3Start 2019-10
  24. A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver TransplantationWithdrawnNCT03634683Study sitePhase 1/Phase 2Start 2018-08
  25. A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver TransplantationStatus unknownNCT02719782Study sitePhase 1Start 2015-07
  26. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownNCT03313596Study sitePhase 3Start 2013-03
  27. Urea Cream Treatment Sorafenib-Associated HSFR in HCCCompletedNCT01934829Study sitePhase 2Start 2009-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 15 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
15
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 1120232024: 2220242025: 332025

16 hospitals in Guangzhou for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AINutrition & recoveryPeritoneal spread & advanced disease
Departments in papersPathology / laboratory medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led15
  1. An emerging entity of gastric adenocarcinoma: clinicopathological features and differential diagnosis of gastric adenocarcinoma of fundic-gland type in 25 retrospective cases.2026Virchows Archiv : an international journal of pathology
  2. Tepotinib interaction triggers a slight effect on the overall stability of hemoglobin protein, reinforcing the potential suitability as a drug candidate against gastric cancer.2025International journal of biological macromolecules
  3. PUF60 Promotes Chemoresistance Through Drug Efflux and Reducing Apoptosis in Gastric Cancer.2025International journal of medical sciencesFree full text
  4. Combined Oxaliplatin with 5-Fluorouracil for Effective Chemotherapy Against Gastric Cancer in Animal Model.2025International journal of nanomedicineFree full text
  5. Mitochondrial dysfunction induced by HIF-1α under hypoxia contributes to the development of gastric mucosal lesions.2024Clinical and translational medicineFree full text
  6. Prognostic value of a modified pathological staging system for gastric cancer based on the number of retrieved lymph nodes and metastatic lymph node ratio.2024PeerJFree full text
  7. CD45- erythroid progenitor cells promote lymph node metastasis in gastric cancer by inducing a hybrid epithelial/mesenchymal state in lymphatic endothelial cells.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  8. Hypoxia-induced ebv-circLMP2A promotes angiogenesis in EBV-associated gastric carcinoma through the KHSRP/VHL/HIF1α/VEGFA pathway.2022Cancer letters
  9. ebv-circRPMS1 promotes the progression of EBV-associated gastric carcinoma via Sam68-dependent activation of METTL3.2022Cancer letters
  10. EBV-Induced CXCL8 Upregulation Promotes Vasculogenic Mimicry in Gastric Carcinoma via NF-κB Signaling.2022Frontiers in cellular and infection microbiologyFree full text
  11. Gastroesophageal reflux is associated with an increased risk of gastric cardiac polyps: a case-control study of 140 cases.2021Annals of palliative medicine
  12. Prognostic Value of Tumor-Infiltrating Lymphocytes and Tertiary Lymphoid Structures in Epstein-Barr Virus-Associated and -Negative Gastric Carcinoma.2021Frontiers in immunologyFree full text
  13. Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity.2021International journal of biological sciencesFree full text
  14. A Smart Multifunctional Nanoparticle for Enhanced Near-Infrared Image-Guided Photothermal Therapy Against Gastric Cancer.2021International journal of nanomedicineFree full text
  15. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)1
  1. [Completely laparoscopic radical treatment of distal gastric cancer through natural orifice specimen extraction surgery: past, present, and future].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status4
  1. Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric CancerStatus unknownNCT05545436Lead sponsorPhase 2Start 2022-09
  2. Single-center Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric CancerStatus unknownNCT02219854Lead sponsorN/AStart 2014-07
  3. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Study sitePhase 3Start 2016-01
  4. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Guangzhou for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Guangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Endoscopy-Assisted Laparoscopic Resections for Gastric Gastrointestinal Stromal Tumors: A Retrospective Study.2017Journal of laparoendoscopic & advanced surgical techniques. Part A

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025

14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & risk

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

5 hospitals in Guangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

23 hospitals in Guangzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)3
  1. Prediction of K562 Cells Functional Inhibitors Based on Machine Learning Approaches.2019Current pharmaceutical design
  2. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.2018Stem cells translational medicine
  3. Up-regulation of NKG2A inhibitory receptor on circulating NK cells contributes to transfusion-induced immunodepression in patients with β-thalassemia major.2016Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Guangzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 39 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 8.0%.

Papers led
39
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 121220212022: 7720222023: 8820232024: 8820242025: 442025

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06763848

    Age 18 years to 65 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  2. Recruiting
    Cohort Study on Neuroimmune Diseases in the Reproductive Age
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT07653984

    Age 20 years to 55 years; women only (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  3. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatmentImaging
Departments in papersNeurologyPathology / laboratory medicine
Papers it led39
  1. Impact of Treatment Delay and Prognostic Factors in Acute Myelitis of Neuromyelitis Optica Spectrum Disease.2025Brain and behaviorFree full text
  2. Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4-IgG-positive neuromyelitis optica spectrum disorder during acute attacks.2025British journal of clinical pharmacology
  3. Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.2025Journal of neurology
  4. Risk of hepatitis B and tuberculosis reactivation in patients with neuromyelitis optica spectrum disorder undergoing B cell depletion therapy.2025Multiple sclerosis and related disorders
  5. A comparative study of hypothalamic involvement in patients with myelin oligodendrocyte glycoprotein antibody-associated disease, neuromyelitis optica spectrum disorder, and multiple sclerosis.2024European journal of neurologyFree full text
  6. Hypothalamic Dysfunction, Bilateral Vertical Gaze Palsy, and Psychiatric Symptoms in Neuromyelitis Optica Spectrum Disorders: A Case Report.2024Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  7. Probiotics-regulated lithocholic acid suppressed B-cell differentiation in neuromyelitis optica spectrum disorder.2024Journal of neuroimmunology
  8. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis.2024Multiple sclerosis and related disorders
  9. Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study.2024Multiple sclerosis and related disorders
  10. Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease.2024Multiple sclerosis and related disorders
  11. Lycium barbarum glycopeptide ameliorates motor and visual deficits in autoimmune inflammatory diseases.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  12. Astrocyte-secreted C3 signaling impairs neuronal development and cognition in autoimmune diseases.2024Progress in neurobiology
  13. Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment.2023BMC neurologyFree full text
  14. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks.2023European journal of neurology
  15. Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation.2023Glia
  16. Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder.2023JAMA neurologyFree full text
  17. Predictors for acute respiratory failure in AQP4-IgG-positive neuromyelitis optica spectrum disorders patients with medullary lesions.2023Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  18. Decreased kynurenine in cerebrospinal fluid and potential role in neuromyelitis optica spectrum disorder.2023Journal of neurochemistry
  19. A novel rare variant of CNPY3 from familial NMOSD impairs the TLR-mediated immune response.2023Journal of neuroimmunology
  20. Inhibition of complement C3 signaling ameliorates locomotor and visual dysfunction in autoimmune inflammatory diseases.2023Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  21. Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation.2022European journal of neurology
  22. Gut Microbiome and Bile Acid Metabolism Induced the Activation of CXCR5+ CD4+ T Follicular Helper Cells to Participate in Neuromyelitis Optica Spectrum Disorder Recurrence.2022Frontiers in immunologyFree full text
  23. Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.2022Journal of neuroimmunology
  24. Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases.2022Journal of neuroimmunology
  25. Clinical and genetic analysis of familial neuromyelitis optica spectrum disorder in Chinese: associated with ubiquitin-specific peptidase USP18 gene variants.2022Journal of neurology, neurosurgery, and psychiatry
  26. Social participation and quality of life among patients with neuromyelitis optica spectrum disorders: The mediating effects of depression.2022Multiple sclerosis and related disorders
  27. Steroid-induced central serous chorioretinopathy in neuromyelitis optica spectrum disorders: a case report.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  28. Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study.2021BMC neurologyFree full text
  29. Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4-IgG-seropositive neuromyelitis optica spectrum disorder.2021Brain and behaviorFree full text
  30. Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder.2021Brain and behaviorFree full text
  31. Whole-exome sequencing reveals the major genetic factors contributing to neuromyelitis optica spectrum disorder in Chinese patients with aquaporin 4-IgG seropositivity.2021European journal of neurology
  32. Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study.2021Frontiers in immunologyFree full text
  33. Hypothalamic lesions in neuromyelitis optica spectrum disorders: exploring a scoring system based on magnetic resonance imaging.2021Japanese journal of radiology
  34. High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  35. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.2021Journal of neurochemistry
  36. Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.2021Journal of neuroimmunology
  37. The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.2021Journal of neuroimmunology
  38. Clinical Characteristics of Chinese Male Patients with Aquaporin-4 Antibody-Positive Late-Onset Neuromyelitis Optica Spectrum Disorder.2021Neuroimmunomodulation
  39. Male patients with neuromyelitis optica spectrum disorders: different clinical characteristics and worse steroid treatment response.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
All its trials on ClinicalTrials.gov, any status5
  1. Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum DisorderRecruitingNCT06763848Lead sponsorN/AStart 2025-04
  2. Cohort Study on Neuroimmune Diseases in the Reproductive AgeRecruitingNCT07653984Lead sponsorStart 2024-04
  3. Treatment Response Among Chinese Neuromyelitis Optica Spectrum DisordersStatus unknownNCT04101058Lead sponsorStart 2019-01
  4. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  5. An Diagnostic Cohort on AQP4-Immunoglobulin G Detection KitCompletedNCT04388072Study siteStart 2020-05
More papers found outside PubMed (not counted)4
  1. The Risk of Hepatitis B and Tuberculosis Reactivation in Patients with Neuromyelitis Optica Spectrum Disorder Treated with B-Cell Depletion Therapy (P7-8.010)2025Neurologyarticle
  2. New Insights Into the Metabolic Capacity of Gut Microbiota in Coordinating the Efficacy of Mycophenolate Mofetil in Neuromyelitis Optica Spectrum Disorders2022Research Squarepreprint
  3. Research progress of neuroregeneration in neuromyelitis optica spectrum disorders2022DOAJ (DOAJ: Directory of Open Access Journals)article
  4. Research progress of single⁃cell omics in central nervous system immune diseases2022DOAJ (DOAJ: Directory of Open Access Journals)article

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution

8 hospitals in Guangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Cohort Study on Neuroimmune Diseases in the Reproductive Age
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT07653984

    Age 20 years to 55 years; women only (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  2. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

  3. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

3 hospitals in Guangzhou for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRevascularisation surgeryImaging & blood flowStroke & bleeding outcomes
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led no English-language PubMed papers on Wilson disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Guangzhou for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver FailureStatus unknownNCT03589820Lead sponsorN/AStart 2018-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 22 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 8.3%.

Papers led
22
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 3320232024: 0020242025: 992025

12 hospitals in Guangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPathology / laboratory medicine
Papers it led22
  1. Glymphatic dysfunction as an indicator of disease burden and a potential biomarker in anti-NMDAR encephalitis.2026Psychiatry and clinical neurosciences
  2. Overlapping autoimmune encephalitis with tripartite autoantibody positivity (NMDAR, GFAP, mGluR5) associated with papillary thyroid carcinoma: a case report.2025BMC neurology
  3. Elevated Prolactin Levels Are Associated With Increased Severity and Psychiatric Symptoms in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2025Brain and behavior
  4. IRF7 in peripheral monocytes drives BBB disruption in anti-NMDAR encephalitis.2025Brain, behavior, and immunity
  5. Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti-NMDAR Encephalitis.2025CNS neuroscience & therapeutics
  6. Serum neuron-specific enolase can predict the severity and outcome of anti-N-methyl-D-aspartate receptor encephalitis.2025Clinica chimica acta; international journal of clinical chemistry
  7. Immunoregulatory programs in anti-N-methyl-D-aspartate receptor encephalitis identified by single-cell multi-omics analysis.2025Clinical and translational medicine
  8. Machine Learning and Shapley Additive Explanations Value Integration for Predicting the Prognostic of Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Model Development and Evaluation Study.2025JMIR medical informatics
  9. Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks.2025Life sciences
  10. Alterations of long-range association fibers in patients with anti-N-methyl-D-aspartate receptor encephalitis.2025NeuroImage. Clinical
  11. Serum neurofilament light chain is associated with disturbed limbic-based functional connectivity in patients with anti-NMDAR encephalitis.2023Journal of neurochemistry
  12. Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti-N-methyl-d-aspartate receptor encephalitis.2023Journal of neuroimmunology
  13. Transfer of patient's peripheral blood mononuclear cells (PBMCs) disrupts blood-brain barrier and induces anti-NMDAR encephalitis: a study of novel humanized PBMC mouse model.2023Journal of neuroinflammation
  14. Simple and effective serum biomarkers potential for predicting status epilepticus in anti-N-methyl-D-aspartate receptor encephalitis.2022BMC neurology
  15. Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases.2022Journal of neuroimmunology
  16. Dysregulated CD40 and CD40 ligand expression in anti-N-methyl-d-aspartate receptor encephalitis.2022Journal of neuroimmunology
  17. Serum NfL associated with anti-NMDA receptor encephalitis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  18. Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated with Ovarian Teratoma in South China-Clinical Features, Treatment, Immunopathology, and Surgical Outcomes of 21 Cases.2021Disease markers
  19. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is associated with IRF7, BANK1 and TBX21 polymorphisms in two populations.2021European journal of neurology
  20. Successful treatment with immunoadsorption therapy in four patients with severe and refractory anti-N-methyl-D-aspartate receptor encephalitis.2021Journal of clinical apheresis
  21. Association of serum Gasdermin D with anti-N-methyl-D-aspartate receptor encephalitis.2021Journal of neurochemistry
  22. Protein A immunoadsorption for the treatment of refractory anti-N-methyl-d-aspartate receptor encephalitis: A single-center prospective study.2021Journal of the neurological sciences
Earlier papers (2016–2020)9
  1. HLA class II allele DRB1*16:02 is associated with anti-NMDAR encephalitis.2019Journal of neurology, neurosurgery, and psychiatry
  2. Serum cystatin C and anti-N-methyl-D-aspartate receptor encephalitis.2018Acta neurologica Scandinavica
  3. Serum complement levels in anti-N-methyl-d-aspartate receptor encephalitis.2018European journal of neurology
  4. Anti-thyroid antibodies and thyroid function in anti-N-methyl-d-aspartate receptor encephalitis.2018Neurochemistry international
  5. Serum Bilirubin and Albumin in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2018Neuroimmunomodulation
  6. Serum uric acid and anti-N-methyl-d-aspartate receptor encephalitis.2017Neurochemistry international
  7. Low serum vitamin D levels and anti-N-methyl-d-aspartate receptor encephalitis: A case-control study.2017Neurochemistry international
  8. [Ovarian tumor associated with anti-N-methyl-D-aspartate receptor encephalitis: a report of 15 cases].2017Zhonghua yi xue za zhi
  9. Brainstem and vestibulocochlear nerve involvement in relapsing-remitting anti-NMDAR encephalitis.2016Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR AntibodiesNot yet recruitingNCT07858175Lead sponsorStart 2026-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Guangzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

7 hospitals in Guangzhou for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. The value of endografts in the surgical management of arterial lesions secondary to Behçet disease.2017Journal of vascular surgery
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

5 hospitals in Guangzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

20 hospitals in Guangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05190848

    Age 16 years to 65 years (registered criteria)

    Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Guangzhou for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. In Vivo Assessment of Neurodegeneration in Type C Niemann-Pick Disease by IDEAL-IQ.2018Korean journal of radiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

9 hospitals in Guangzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Guangzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Diagnosis and treatment procedures and health management for patients with hereditary angioedema].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中山大学附属第三医院

Third Affiliated Hospital of Sun Yat-sen University

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Third Affiliated Hospital of Sun Yat-Sen University; Third Affiliated Hospital of Sun Yat‑sen University; Third Affiliated Hospital of Sun Yat-sen University (SYSU); Third Affiliated Hospital of Zhongshan Medical University

Suggest a correctionDownload the data